☆ 4.7 Article

Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study

Fabrizio Vernieri et al.

Summary: This study evaluated the 1-year effectiveness and tolerability of galcanezumab in real-life treatment of high-frequency episodic and chronic migraine. The results showed that a majority of patients experienced a significant reduction in monthly migraine days for at least 9 months. Triptan response, lower body mass index, and an early reduction in migraine days were identified as predictive factors for a persistent response.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Add to Collection

Review Clinical Neurology

Sleep and Chronobiology as a Key to Understand Cluster Headache

Laura Pilati et al.

Summary: This article explores the relationship between cluster headaches and sleep, chronobiology, and circadian rhythm. It suggests that genetic factors and anatomical structures such as the hypothalamus may influence the periodicity and onset of cluster headaches. Additionally, sleep disturbances are commonly observed in cluster headache patients. The purpose of this review is to analyze this link in order to interpret the pathophysiology of cluster headaches and consider potential therapeutic implications.

NEUROLOGY INTERNATIONAL (2023)

Add to Collection

Article Clinical Neurology

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti et al.

Summary: This study investigated the effectiveness, safety, and tolerability of fremanezumab in a real-life population of high-frequency episodic or chronic migraine patients. The results showed that fremanezumab was effective in reducing migraine days, headache days, analgesic intake, and improving quality of life in both types of migraine. Younger age emerged as a potential predictor for positive treatment response.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Article Clinical Neurology

Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study

Gaia Pellitteri et al.

Summary: Migraine and sleep have a complex relationship, where poor sleep may trigger migraine attacks and migraine is often associated with sleep disorders. This study investigated sleep changes in patients with migraine treated with erenumab using validated questionnaires and home polysomnography.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine-A Real-Life Study

Magdalena Nowaczewska et al.

Summary: This study aimed to investigate the relationship between baseline clinical parameters and cerebral blood flow (CBF) with the efficacy of monoclonal antibodies (mAbs). The study found that patients with lower baseline mean blood flow velocity (Vm) in the cerebral arteries had a better response to mAbs treatment. Additionally, unilateral pain localization, higher HIT-6 scores, and absence of family history of migraine were associated with better responsiveness to mAbs.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine

Alicia Alpuente et al.

Summary: This study aimed to analyze salivary calcitonin gene-related peptide (CGRP) levels in patients with migraine, predict erenumab response based on baseline CGRP levels, and evaluate CGRP changes post-treatment. The results showed that patients with migraine had higher CGRP levels compared to healthy controls, and the presence of depressive symptoms increased salivary CGRP levels. Additionally, baseline salivary CGRP concentration was associated with treatment response to erenumab for patients with episodic migraine.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine

Luigi Francesco Iannone et al.

Summary: Anti-calcitonin gene-related peptide antibodies appear to have a significant impact on the prodromal and accompanying symptoms of migraine, reducing the frequency and intensity of migraine attacks.

CEPHALALGIA (2022)

Add to Collection

Article Clinical Neurology

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience

Claudia Altamura et al.

Summary: The study found that more than half of patients with chronic migraine who received galcanezumab treatment in real-life settings persistently converted to episodic migraine during a one-year period.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Piero Barbanti et al.

Summary: This study investigates the predictors of response to antiCGRP mAbs in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). The results show that in HFEM, unilateral pain + unilateral cranial autonomic symptoms are positively associated with >= 50% response. In CM, allodynia + unilateral pain, unilateral cranial autonomic symptoms are positively associated with >= 50% response, while obesity is negatively associated with >= 50% response. This study is important for predicting the response of migraine patients to antiCGRP mAbs.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Review Clinical Neurology

Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis

Konstantina Drellia et al.

Summary: The study found that anti-CGRP mAbs have a more favorable benefit-risk ratio for the prevention of episodic and chronic migraine compared to established treatments, but head-to-head studies are needed to confirm these results.

CEPHALALGIA (2021)

Add to Collection

Review Clinical Neurology

Medication overuse and drug addiction: a narrative review from addiction perspective

Tatiane Teru Takahashi et al.

Summary: Chronic headaches are common in migraineurs and can progress to medication overuse headache (MOH). MOH is caused by overuse of painkillers or other medications. While head pain symptoms associated with medication overuse generally improve after stopping regular medication use, behavioral issues such as drug dependence may still persist.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Migraine and Sleep-An Unexplained Association?

Marta Waliszewska-Prosol et al.

Summary: Migraine and sleep disorders are common chronic diseases with significant negative impacts on society and economy. The association between them is observed but not fully understood, with recent progress in understanding common anatomical structures and pathogenetic mechanisms. Better understanding of these mechanisms in the future will expand treatment options.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Raffaele Ornello et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

Antonio Russo et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

A prospective real-world analysis of erenumab in refractory chronic migraine

Giorgio Lambru et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Review Clinical Neurology

Migraine and sleep disorders: a systematic review

Cindy Tiseo et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Editorial Material Clinical Neurology

The American Headache Society's Position Statement on Integrating New Migraine Treatments into Clinical Practice - Comments

James A. Charles et al.

HEADACHE (2019)

Add to Collection

Article Clinical Neurology

Erenumab in chronic migraine Patient-reported outcomes in a randomized double-blind study

Richard B. Lipton et al.

NEUROLOGY (2019)

Add to Collection

Review Clinical Neurology

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

Raffaele Ornello et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

Circadian rhythms of migraine attacks in episodic and chronic patients: a cross sectional study in a headache center population

Marina de Tommaso et al.

BMC NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

Uwe Reuter et al.

LANCET (2018)

Add to Collection

Article Clinical Neurology

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart Tepper et al.

LANCET NEUROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Psychology, Multidisciplinary

Sleep and headaches: Relationships between migraine and non-migraine headaches and sleep duration, sleep quality, chronotype, and obstructive sleep apnoea risk

Daniel P. Sullivan et al.

AUSTRALIAN JOURNAL OF PSYCHOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Associations Between Sleep Quality and Migraine Frequency A Cross-Sectional Case-Control Study

Yu-Kai Lin et al.

MEDICINE (2016)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

The therapeutic armamentarium in migraine is quite elderly

Paolo Martelletti

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Calcitonin Gene-Related Peptide Neurons Mediate Sleep-Specific Circadian Output in Drosophila

Michael Kunst et al.

CURRENT BIOLOGY (2014)

Add to Collection

Review Psychiatry

Psychometric properties of the Beck Depression Inventory-II: a comprehensive review

Yuan-Pang Wang et al.

REVISTA BRASILEIRA DE PSIQUIATRIA (2013)

Add to Collection

Article Anesthesiology

Adherence with Migraine Prophylaxis in Clinical Practice

Ariel Berger et al.

PAIN PRACTICE (2012)

Add to Collection

Article Clinical Neurology

Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine

Min Yang et al.

CEPHALALGIA (2011)

Add to Collection

Article Clinical Neurology

The Long-Term Effect of Insomnia on Primary Headaches: A Prospective Population-Based Cohort Study (HUNT-2 and HUNT-3)

Siv S. Odegard et al.

HEADACHE (2011)

Add to Collection

Article Clinical Neurology

Associations between sleep disturbance and primary headaches: the third Nord-Trondelag Health Study

Siv Steinsmo Odegard et al.

JOURNAL OF HEADACHE AND PAIN (2010)

Add to Collection

Article Clinical Neurology

Are Sleep Difficulties Associated With Migraine Attributable to Anxiety and Depression?

Angeliki Vgontzas et al.

HEADACHE (2008)

Add to Collection

Article Clinical Neurology

Migraine prevalence, disease burden, and the need for preventive therapy

R. B. Lipton et al.

NEUROLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.